Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous stromal vascular fraction (Swiss Medica)
- Development stage
- Unknown
- Lead developer
- Swiss Medica
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intraarticular
01
Overview
This autologous cell therapy consists of the stromal vascular fraction (SVF) derived from a patient's own adipose tissue, developed by Swiss Medica XXI Century S.A. for the treatment of knee osteoarthritis. The therapeutic process involves extracting lipoaspirate via liposuction, followed by enzymatic digestion to isolate the SVF, which contains a heterogeneous population of cells including mesenchymal stem cells (MSCs), endothelial cells, and immune cells. Administered as a single intraarticular injection, the SVF cells exert anti-inflammatory and regenerative effects within the joint environment to alleviate pain and potentially repair cartilage damage. The therapy is currently being evaluated in a Phase 2 clinical trial (NCT04050111) to assess its safety and effectiveness in reducing symptoms of knee joint arthrosis.
- Other names
- SVFAutologous SVFAdipose-derived stromal vascular fraction
Beyond the preview
Go deeper on Autologous stromal vascular fraction (Swiss Medica).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Autologous stromal vascular fraction (Swiss Medica).